Business News

Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment …

Read More »

Siemens Healthineers to Acquire Varian Medical for $16.4 Billion

/PRNewswire/ — Varian (NYSE: VAR) today announced that it has entered into a definitive agreement to combine with Siemens Healthineers AG (Frankfurt: SHL) in an all-cash transaction valued at $16.4 billion on a fully diluted basis. Under the terms of the agreement, which has been unanimously approved by Varian’s Board …

Read More »

Guardant Health and Radius Health Partner to Develop Liquid Biopsy Companion Diagnostic for Elacestrant

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader (SERD) being studied in the treatment …

Read More »

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s …

Read More »

UCB and Roche Collaborate to Develop Antibody Treatment for People Living with Alzheimer’s Disease

BRUSSELS, July 29, 2020 /PRNewswire/ — UCB today announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD). The transaction remains subject to obtaining antitrust clearance and …

Read More »

AstraZeneca to Pay Daiichi Sankyo Up to $6 Billion for its New Cancer Drug

AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumor types. DS-1062 is currently in development for the …

Read More »

Centogene and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in …

Read More »

Lilly and Zentalis Collaborate to Evaluate the Combination of Abemaciclib with an Oral SERD Product Candidate in Advanced Breast Cancer

NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a clinical collaboration agreement with Eli Lilly and Company (NYSE: LLY, “Lilly”) in which …

Read More »

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine Against COVID-19

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up …

Read More »

Pfizer and BioNTech Announce an Agreement with US Government for up to 600 Million Doses of mRNA-based COVID-19 Vaccine Candidate

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million …

Read More »